DALLAS, Aug. 14, 2026
Lantern Pharma Inc. is strengthening its position at the intersection of artificial intelligence and precision oncology, with the company’s latest business update highlighting the transformation of its AI capabilities into a dedicated commercial technology business. The company has formally established Open Medicine AI (OMAI) as a separate company to commercialize its multi-agentic AI co-scientist platform, previously launched as withZeta.ai. OMAI operates under commercial licensing agreements with Lantern Pharma and is designed to provide AI-powered capabilities across medicinal chemistry, computational biology, biomarker discovery, clinical trial strategy and clinical oncology. The company plans to seek external capital for OMAI while retaining ownership of the business initially. Lantern said the separation is intended to allow the AI platform and oncology drug-development operations to pursue different funding and valuation models while maintaining access to the technology across its drug pipeline.
Open Medicine AI Turns AI Research Into a Commercial Platform
The establishment of Open Medicine AI represents the most significant technology-focused development from Lantern Pharma’s second-quarter update. OMAI is being positioned as a commercial AI software business, offering tiered subscriptions and enterprise agreements for biotechnology and pharmaceutical companies, academic medical centers, life sciences investors and disease-focused organizations. Its platform coordinates specialized AI agents capable of addressing different stages of biomedical research rather than functioning as a single-purpose chatbot. The platform includes capabilities spanning computational biology, medicinal chemistry, translational science, biomarkers and clinical oncology, with Lantern describing the system as an AI co-scientist designed to accelerate research workflows. In July, the company launched ZetaOmics, a computational-biology module intended to independently design analyses, execute them on biological datasets, explain methodological decisions and generate publication-quality outputs with an auditable record. Lantern has also established an AI Center of Excellence in Bengaluru, India, expanding the development infrastructure supporting its AI strategy.
AI-Driven Precision Oncology Continues Into Clinical Development
Lantern’s AI strategy remains directly connected to its oncology pipeline, where the company uses its proprietary RADR artificial intelligence and machine-learning platform to identify drug-development opportunities, biomarkers and patient populations. The company reported emerging findings from the HARMONIC Phase 2 trial of LP-300, with the strongest signal observed in patients carrying the EGFR exon 21 L858R mutation. Among L858R patients who completed six cycles, median progression-free survival reached 8.9 months, compared with 8.4 months across the overall L858R cohort, while the subgroup showed a reported hazard ratio of 0.37. Based on these observations, the FDA reviewed proposed protocol amendments without objection, allowing future enrollment to focus on the L858R population and extending the maximum LP-300 treatment duration from six to eight cycles. Lantern is also advancing LP-184 (zirdafulven) through biomarker-selected clinical development, including an EMA-cleared bladder cancer study using a dual-biomarker approach. These developments demonstrate how Lantern is attempting to translate AI-generated biological insights into targeted clinical programs.
Advertisement
Lantern Builds Two AI-Enabled Value Creation Engines
With OMAI now structured as a separate company, Lantern Pharma is effectively pursuing two connected businesses: an AI-enabled precision oncology developer and a commercial AI technology platform. Lantern said OMAI will initially remain wholly owned while seeking additional investment, with a longer-term objective of potentially becoming an independently listed company. Importantly, the separation does not remove Lantern’s ability to use the AI platform across its oncology programs, including LP-184, LP-284 and LP-300. The company said its AI-driven development model has enabled selected programs to progress from initial AI insights to first-in-human clinical trials in approximately two to three years, with reported development costs of roughly $2 million to $3 million per program. Financially, Lantern ended the second quarter with approximately $7.4 million in cash, cash equivalents and marketable securities, while its second-quarter operating loss declined approximately 25% year over year to $3.5 million. The financial results are secondary to the broader technology story: Lantern is attempting to turn AI from an internal drug-discovery tool into a standalone commercial platform while continuing to use the technology to drive precision oncology development.
Source:Lantern Pharma, press relese
